Jennifer Kayden Lee - 03 Nov 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
Issuer symbol
RYTM
Transactions as of
03 Nov 2023
Net transactions value
-$1,696
Form type
4
Filing time
07 Nov 2023, 18:17:13 UTC
Previous filing
07 Sep 2023
Next filing
13 Nov 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $544 +80 +4.9% $6.80 1,727 03 Nov 2023 Direct
transaction RYTM Common Stock Sale $2,240 -80 -4.6% $28.00 1,647 03 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -80 -0.12% $0.000000 67,592 03 Nov 2023 Common Stock 80 $6.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
F2 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.